Close Menu
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
Trending

NFL Expert Suggests Bold Trade the NY Giants Should Consider

July 7, 2025

Trump Administration Aims to Deport Abrego Garcia Ahead of His Trial, According to Justice Department

July 7, 2025

Understanding the Energy Consumption of Your AI Prompt: It Varies

July 7, 2025
Facebook X (Twitter) Instagram
Smiley face Weather     Live Markets
  • Newsletter
  • Advertise
Facebook X (Twitter) Instagram YouTube
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
InfoQuest Network
  • News
  • World
  • Politics
  • Business
  • Finance
  • Entertainment
  • Health & Wellness
  • Lifestyle
  • Technology
  • Travel
  • Sports
  • Personal Finance
  • Billionaires
  • Crypto
  • Innovation
  • Investing
  • Markets
  • Startup
  • Immigration
  • Science
Home»Business»Markets»Choosing Between Pfizer and Eli Lilly Stocks: Which is the Better Investment?
Markets

Choosing Between Pfizer and Eli Lilly Stocks: Which is the Better Investment?

News RoomBy News RoomJuly 12, 20240 ViewsNo Comments2 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email Reddit Telegram WhatsApp

Eli Lilly (LLY) is currently positioned as a better investment option compared to its industry peer Pfizer (PFE). This is due to various factors such as historical performance, revenue growth, profitability, and debt position. Over the last three years, LLY stock has outperformed PFE stock significantly, with a 450% increase compared to PFE’s decline of 15%. While PFE has shown better revenue growth in recent years, the future seems to belong to Eli Lilly, with an expected annual growth rate of 23% over the next three years compared to Pfizer’s projected 3% growth.

Pfizer experienced a surge in revenue due to high demand for its Covid-19 vaccine and treatment, but this trend reversed in 2023, leading to a 42% decrease in total sales. On the other hand, Eli Lilly’s revenue growth can be attributed to market share gains for key drugs like Mounjaro, Verzenio, and Zyprexa, with expectations for explosive growth in the coming years. Additionally, Eli Lilly has a solid pipeline potential, particularly in obesity drugs, which is reflected in its rising price-to-sales ratio.

In terms of profitability and debt position, Eli Lilly has shown a stronger performance than Pfizer. While Pfizer’s operating margin declined and debt levels rose due to the Seagen acquisition, Eli Lilly saw an increase in its operating margin and maintained low levels of debt. This indicates that Eli Lilly is more profitable and has a better debt position, making it a more attractive investment choice for investors.

Kangen Water

From a valuation perspective, PFE stock appears attractive trading at a lower multiple of 2.8x sales compared to LLY’s multiple of 23.5x sales. However, the rise in valuation for Eli Lilly is justified given the expected uptick in revenues from key drugs like Mounjaro and Zepbound. With regulatory approvals for more indications likely in the future, there is potential for further upside in peak sales for Eli Lilly’s key drugs, making it a more favorable pick over Pfizer.

Overall, despite a significant 450% rise in the last three years, Eli Lilly is expected to continue outperforming Pfizer in the next three years. While both stocks may see an increase in value, the growth in LLY is projected to surpass that of PFE. Investors looking for potential growth opportunities in the pharmaceutical industry may find Eli Lilly to be a more promising investment choice based on its strong revenue growth, profitability, and future prospects.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related News

Three Dividend Stocks Offering More than 7% Returns in Any Market

August 9, 2024

Reflections on 2008: Navigating a Challenging Economy with Ford

August 9, 2024

Can Baidu’s AI Innovations Drive Stock Growth After Q2 Results?

August 8, 2024

Anticipating the Outcome of Wheaton Precious Metals’ Q2 Results

August 8, 2024

What Factors are Contributing to the Decline in Nintendo Stock Prices?

August 8, 2024

Markets Aiming for Back-to-Back Winning Days

August 8, 2024
Add A Comment
Leave A Reply Cancel Reply

Top News

Trump Administration Aims to Deport Abrego Garcia Ahead of His Trial, According to Justice Department

July 7, 2025

Understanding the Energy Consumption of Your AI Prompt: It Varies

July 7, 2025

Unbelievable Robot Vacuum: Features Impressive Arms and Navigation – Now $400 Off for Prime Day!

July 7, 2025

Subscribe to Updates

Get the latest news and updates directly to your inbox.

Advertisement
Kangen Water
InfoQuest Network
Facebook X (Twitter) Instagram YouTube
  • Home
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 Info Quest Network. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.